Please ensure Javascript is enabled for purposes of website accessibility

Why Valeant Pharmaceuticals International Stock Is Moving Higher Today

By George Budwell - Updated May 8, 2018 at 3:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pace of Valeant's turnaround may be picking up.

What happened

Shares of the embattled drugmaker Valeant Pharmaceuticals International (BHC -2.17%) rose by as much as 17.1% today on extremely heavy volume. The catalyst?

Valeant's shares are responding positively to three material events:

  1. The company reported stronger-than-expected sales in the first quarter, beating consensus by a healthy $45 million.
  2. Based on the strength of its Bausch & Lomb and branded drug segments, Valeant also revised its annual revenue guidance for the year to between $8.15 billion and $8.35 billion. The company's previous guidance called for annual sales to range from $8.10 billion to $8.30 billion.
  3. Lastly, Valeant announced that it will change its name this coming July to Bausch Health Companies Inc. in order to move past the misdeeds of the company's former management team.
An origami bull towering over a cowering bear

Image source: Getty Images.

As of 2:30 p.m. EDT, Valeant's shares are still up by a noteworthy 8.15% on the back of this news.

So what

Investors are obviously happy that the company is finally starting to see its Bausch & Lomb and branded drug businesses pick up in a meaningful way. That being said, Valeant's efforts to whittle down its monstrous debt load are starting to slow down as predicted.

In the first quarter of 2018, for instance, the company reported that it doled out $280 million toward its debt load, which now stands at an unseemly $25.6 billion. Prior to this quarter, Valeant had been averaging $827 million in debt reduction on a quarterly basis, thanks to a slew of asset divestitures.

Now what

Although a name change is arguably a good idea for Valeant at this point, the fact remains that the company is drowning in debt and it simply doesn't have the assets in place to change this fundamental problem anytime soon. So, even though Valeant's core growth drivers are starting to show signs of life, this stock remains a high-risk play.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$9.93 (-2.17%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.